Lakefront Biotherapeutics | GLPG - Gross Profit On Sales


Lakefront Biotherapeutics reported EUR1.68M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.61B 225M Mar/2026
Biogen USD 1.82B 169.5M Mar/2026
Genmab DKK 977M 13M Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
GRIFOLS EUR 686.84M 56.95M Dec/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Incyte USD 1.17B 217.51M Mar/2026
Merck EUR 3.07B 104M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 3.19B 621M Dec/2025
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026